Novartis Reaches Deal With Watson For Nicotine Replacement Products
This article was originally published in The Tan Sheet
Executive Summary
Watson Pharmaceuticals is expanding the over-the-counter sales base for its smoking cessation line through a partnership with Novartis Consumer Health
You may also be interested in...
Commit Lozenge Generic Equivalent Application Filed
A recent regulatory submission filed with FDA is seeking 180-day exclusivity for a generic version of nicotine replacement therapy lozenges
Watson Private Label Nicotine Gum Launching In September
Watson Pharmaceuticals will introduce its private label nicotine polacrilex gum "before the end of the third quarter," the company announced during a conference call with securities analysts Aug. 5. Retail chains that have agreed to carry the product include CVS, Walgreen, Rite-Aid, Eckerd, American Stores and Wal-Mart.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC